The morphological study of anti-alterative properties of the drug “Diclocor” under conditions of furasolidone-isadrine myocarditis in rats

Authors

  • I. A. Zupanets National University of Pharmacy, Ukraine
  • S. K. Shebeko National University of Pharmacy, Ukraine
  • O. S. Russkin National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/cphj.15.1365

Keywords:

morphological study, alterative lesion, Diclocor, rat’s myocardium

Abstract

The article presents the results of morphological study by assessment of the antialterative activity of the drug Diclocor (capsules) of PJSC SPC "Borschagivskiy CPP" production, which is an original composition of NSAID diclofenac sodium with flavonoid quercetin. During the study was calculated the values of the mass coefficients of hearts (MCH), analyzed morphostructural changes and conducted semi-quantitative assessment of the degree of necrotic lesion in rat’s myocardium. According to the results of the conducted study it was found that the effectiveness of the drug Diclocor, its ability to normalize values MCH in rats with furasolidone-isadrine lesion of myocardium was 79% and was significantly higher than in the reference objects. The results of semi-quantitative assessment of the degree of necrotic lesion in rat’s myocardium confirm the ability of the study drug to restore the morphostructures of the rat’s myocardium at conditions of alterative lesion. Pronounced antiinflammatory effect of Diclocor on the model of furasolidone-isadrine myocardial lesion in rats allows to substantiate the prospects of application of the investigated object as a cardioprotective remedy.

References

Непомнящих Л.М., Лушникова Е.Л., Ларионов П.М., Шурыгин М.Г. Регенерация миокарда: Пролиферативный потенциал кардиомиоцитов и индукция кардиомиогенеза при альтеративной и пластической недостаточности сердца // Вестник РАМН. – 2010. – № 5. С. 3-11.

Meek I.L., Picavet H.S., Vonkeman H.E. et al. Increased cardiovascular risk factors in different rheumatic diseases with the general population // Oxford (United Kingdom). — Р. Rheumatology. – 2012 – 52 (1). – Р. 210-216

World Health Statistics 2012. - WHO, 2012. - 176 p. - http://www.who.int/healthinfo/ EN_WHS2012_Full.pdf.

T. Gusdinar, R. Herowati, R.E. Kartasasmita and I.K. Adnyana, Anti-inflammatory and Antioxidant Activity of Quercetin-3, 3’, 4’-Triacetate. Journal of Pharmacology and Toxicology.2011, 6: 182-188.

Зайченко Г.В. НПВП: что нового в начале XXI века? // Медична газета «Здоров’я України». – Квітень 2014 р. – № 7 (332). – С. 30-31.

European convention for the protection of vertebrate animals used for experimental and other scientific purpose: Council of Europe 18.03.1986. - Strasbourg, 1986. - 52 p.

Доклинические исследования лекарственных средств: Методические рекомендации / Под ред. А.В. Стефанова. – К: Авиценна. – 2002. – 528 с.

Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. – 3-е изд. – Москва: МедиаСфера. – 2006. – 312 с.

Лапач С.Н. Статистические методы в медико-биологических исследованиях с использованием Excel / С.Н. Лапач, А.В. Чубенко, П.Н. Бабич – Киев: Морион – 2000. – 320 с.

Кардиоваскулярная патология при ревматоидном артрите. Монография/А.А.Дзизинский, Н.А.Храмцова//Иркутск: РИО ГИУВа – 2010. – 150 с.

Genovese M.C., Rubbert-Roth A., Smolen J.S. et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure // J. Rheumatol. 2013, Jun 1;40(6):768-80.

A. D. Hingorani and J. P. Casas, “The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis,” The Lancet. 2012, vol. 379, no. 9822, pp. 1214–1224.

C. P. Chung, J. T. Giles, M. Petri et al., “Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: Comparison with control subjects from the multi-ethnic study of atherosclerosis,” Seminars in Arthritis and Rheumatism. 2012, vol. 41, no. 4, pp. 535–544.

Downloads

Published

2015-12-01

Issue

Vol. 19 No. 4 (2015)

Section

Pre-clinical studies of new drugs

License

Copyright (c) 2015 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).